Virtual Sites—Are they the Future of RWE?

The adoption of virtual sites, that are powered by decentralized clinical trial tools, has increased exponentially in the recent years. As adoption accelerates, so do the possibilities that virtual conduct enables. In this webinar, Science 37 will host a conversation with a group of industry leaders to address challenges faced by the industry and discuss how virtual sites can be implemented to improve real-world data access and long-term follow up.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/rwe

Event Overview:

The adoption of virtual sites, that are powered by decentralized clinical trial tools, has increased exponentially in the recent years. As adoption accelerates, so do the possibilities that virtual conduct enables. Real-world evidence and long-term follow-up studies have especially benefited from decentralized trial elements. In this webinar, Shaalan Beg, MD, MS at Science 37 and Gordon Cummins, VP of RWE COE at Science 37 will host a conversation with a group of leaders to address challenges faced by the industry. The panel will discuss how virtual sites can be implemented to improve real-world data access and long-term follow up. As well as elaborate on the value virtual sites delivered to patients, sponsors, and CROs alike. Learn how virtual site elements are incorporated today, and how the landscape will change in the years to come. Register today.

Key points:

• A discussion on the challenges the industry currently faces with RWE
• A look at the latest approaches sponsors leverage for RWE
• Use cases, study designs and the value delivered to stakeholders

Speakers:

Shaalan Beg, M.D., M.S.C.S
Vice President, Oncology
Science 37

Dr. Shaalan Beg brings a wealth of clinical investigator and research expertise to spearhead Science 37’s agile clinical trials program in oncology — building on its mission to enable universal access for patients and providers, anywhere, and executing plans to grow precision medicine and develop strategic partnerships.

A storied researcher and oncologist, Dr. Beg came to Science 37 from the University of Texas, Southwestern Medical Center in Dallas, TX where he served as Medical Director for the Clinical Research Office at the Simmons Comprehensive Cancer Center and held the position of Director Gastrointestinal Medical Oncology and Associate Professor of Hematology and Medical Oncology.

Nationally, Dr. Beg is a member of the American Society of Clinical Oncology (ASCO) and the ECOG-ACRIN Clinical Research Group, having held several committee positions in those organizations. He is a graduate of ASCO’s Leadership Development Program and has been a member of the Pancreatic Cancer Task Force of the National Cancer Institute (NCI) GI Cancer Steering Committee.

Gordon Cummins
Vice President, Real-World Evidence
COE
Science 37

Gordon Cummins leads the Real-World Evidence (RWE) division at Science 37. He has worked in the real-world evidence space for over 25 years in research, product development, study design, strategic development, and global operations. Gordon has direct experience with health plans/IDN’s, pharmacy/PBM’s, provider networks, associations, and academic institutions

Gordon was the past ISPOR co-chair for classifications of retrospective databases, past member for scientific journals, and has numerous publications/posters/presentations in real-world evidence across multiple indications. He obtained his Undergraduate degree (Mathematics/Actuarial Science) and Master’s degree (statistics) from Southwest Missouri State University.

Chris A. Learn, PhD, PMP
Vice President, Cell and Gene
Therapy Center of Excellence
Parexel

Chris Learn brings 20 years of clinical trial execution and team management experience, Dr. Learn is personally committed, enthusiastic and passionate about translational science. With interests in the strategic development of novel therapeutics, Dr. Learn is a published author and has been a team leader in the registrational buildout, agency submission and regulatory approval of five separate and unique marketed products (YONDELIS®, IMBRUVICA®, KEYTRUDA®, BREYANZI® and ABECMA®).

A former project leader at Duke University, Merck & Co, and Istari Oncology, Dr. Learn has authored numerous clinical trial protocols, including the design, implementation, and execution of a variety of cellular and genetic therapies.

Over the past five years, Dr. Learn has served as a subject matter expert overseeing the clinical development programs of >20 cell and gene therapy programs in rare disease, CNS, pediatrics and oncology for emerging biotech portfolios as well as large cap pharma. His current interests and commitments lie in the phasing of dose, route and administration of cell and gene therapies in the clinic well as how to use innovations in immunotherapy to drive these unique therapies further in terms of improving patient outcomes.

Ariel Bourla
Senior Director Oncology, Data
Science & Digital Health
Janssen

Dr. Ariel Bourla serves as Senior Director on Janssen R&D’s Data Science & Digital Health team, where she leads efforts to apply real-world data and other data science solutions to advance and accelerate Oncology clinical programs. Dr. Bourla holds a strong background in Medical Oncology, Immunology, and Data Science. She spent 6 years at Flatiron Health as a Medical Director and Clinical Trials Lead. In this role, she led research teams executing prospective real-world studies, methodologic and observational research projects, and developed new technologies for sites and sponsors participating in clinical trials.

Dr. Bourla received her MD/PhD training from the Mount Sinai School of Medicine, with a subsequent internship and residency at New York Presbyterian-Columbia University Medical Center, and a Medical Oncology fellowship at Memorial Sloan Kettering Cancer Center. She earned a BA in English Language and Literature from Yale University.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/rwe